Pfizer Inc.

ELREXFIO

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Pfizer Inc.

Elrexfio HCPCS:

J1323

HCPCS Code Descriptor:

Injection, elranatamab-bcmm, 1 mg

Category:

J Code

Elrexfio NDCs:

00069-2522-02, 00069-4494-02

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Subcutaneous

Elrexfio CPT Codes:

-96401 - Chemotherapy administration, subcutaneous or intramuscular; nonhormonal antineoplastic

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Elrexfio:

ELREXFIO is aligned to the J Code: J1323. ELREXFIO is an Oncology drug produced by Pfizer Inc. and administered via the Subcutaneous route of administration.

ACCESS PRICING AND MORE BY REGISTERING

J1323 Added Date:

4/1/24

J1323 Effective Date:

4/1/24

J1323 Deactive Date:

HCPCS Active

Elrexfio billing and coding information can be found through Pfizer Inc. at the link below:
Elrexfio patient assistance information can be found through Pfizer Inc. at the URL: https://www.elrexfio.com/navigating-support-financial-resources
ELREXFIO prescribing information can be found at the link below:
Information regarding ELREXFIO’s potential side effects can be found at MedlinePlus